BAGEL-CAR: Reflections on the Bits to Binders Competition
Abstract
The antigen-binding segment of chimeric antigen receptors (CARs) in CAR-T therapy has emerged as a compelling application of de novo AI protein design. In the Bits to Binders competition, our group submitted 414 BAGEL-CAR designs for CD20-directed CAR binding segments, 38.4% of which were statistically enriched in a pooled CAR-T proliferation screen, the highest among all teams and more than double the next-best. Strikingly, after detailing the three design strategies employed, we show that two of them carry the entire success of our campaign, with both of them outcompeting all the other teams' aggregate results. Crucially, during the competition, we did not refold any of the binders after backbone painting. Had we applied this typical validation step with ESMFold, all experimentally enriched designs would have been filtered out. Our findings show that each filtering step should be stress-tested per biomolecular system and intermediate outputs of design pipelines should be assayed regardless of 'common practice'. Additionally, we appear to be the only team that designed against ESMFold's predicted CD20 dimer geometry, which diverges substantially from the experimentally resolved 6Y97 structure, raising, but not resolving, the possibility that this alternative target geometry contributed to our high hit rate. We hope these reflections help inform the future of effective CAR-T and binder design campaigns.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Validation and analysis of 12,000 AI-driven CAR-T designs in the Bits to Binders competition
Clayton W. Kosonocky, Alex M. Abel, … Rohit Satija·Molecular Systems BiologyPeer-reviewed·Oct 8, 2026
- Sequence and structural determinants of efficacious de novo chimeric antigen receptors
Arthur Chow, Hoyin Chu, … Caleb A. Lareau·bioRxiv·Dec 13, 2025
- Beyond Structure and Affinity: Context-Dependent Signals for de novo Binder Success
Çağlar Bozkurt·bioRxiv·Apr 15, 2026
- Engineering de novo binder CAR-T cell therapies with generative AI
Markus Mergen, Daniela Abele, … Andrea Schmidts·bioRxiv·Nov 25, 2024
- Development of AI-designed protein binders for detection and targeting of cancer cell surface proteins
Bianca Broske, Sophie C. Binder, … Michael Hölzel·bioRxiv·May 11, 2025
- Discovery 4.0: An Escape-Aware Computational Platform for Resistance-Proofed Chimeric Antigen Receptor Design
Alireza Daneshvar, Rakhshan Mashayekhi, Mohammadhossein Sharifnia·bioRxiv·May 27, 2026